Critical Illness, Inflammation, Myocardial Infarction
Conditions
Keywords
Myocardial Infarction, Inflammation, Critical Illness, Necrosis, Sepsis, Respiratory Insufficiency, Myocardial Ischemia, Cardiovascular Diseases, Heart Diseases, Vascular Diseases
Brief summary
Type 2 myocardial infarction (MI) is defined as myocardial necrosis that results from an imbalance of myocardial oxygen supply and demand. Although type 2 MI is highly prevalent in patients with critical illness and strongly associated with mortality, the pathophysiology remains poorly understood. Inflammation is central to the development of atherosclerosis, plaque rupture, and other subtypes of MI, but the role of inflammation in type 2 MI and myocardial necrosis has not been defined. The investigators aim to to delineate the mechanistic role of inflammation in myocardial necrosis and type 2 MI complicating critical medical illness.
Interventions
None listed
Sponsors
NYU Langone Health
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥21 years of age * admitted to the Medical Intensive or Coronary Care Units * sepsis or respiratory failure * clinically indicated troponin measurement within 24 hours of ICU admission
Exclusion criteria
* unstable angina or Type 1 MI * percutaneous or surgical coronary revascularization within 7 days * heart failure exacerbation * primary valvular disorder * aortic dissection * infiltrative heart disease or hypertrophic cardiomyopathy * myocarditis * pulmonary embolism * electrocardiogram with \>1mm ST segment elevation in two consecutive leads * serum cardiac troponin \>99th percentile URL but no clear rise or fall pattern * history of chronic inflammatory disease * use of therapeutic-dose anticoagulants / antiplatelet agents other than aspirin * pregnant or incarcerated * enrolled in a competing study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Leukocyte-platelet aggregates | Day 1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Neutrophil-platelet aggregates | Day 1 | — |
| Leukocyte-platelet aggregates | Day 10 | Participants will be followed for the duration of hospital stay, an expected average of 10 days. |
| Monocyte-platelet aggregates | Day 1 | — |
Other
| Measure | Time frame |
|---|---|
| EndoPAT score | Day 1 |
| surface L-selectin | Day 1 |
| soluble L-selectin | Day 1 |
| surface CD11b | Day 1 |
Countries
United States
Outcome results
None listed